G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Rubinstein, Mark P ^a,b   Salem, Mohamed L ^b,c   Doedens, Andrew L ^a   Moore, Caitlin J ^b   Chiuzan, Cody ^b   Rivell, Guillermo L ^b   Cole, David J ^b   Goldrath, Ananda W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Tanta University   (Egypt)

Author keywords

Antibody cytokine complexes; G CSF; Myeloid cells; Neulasta; Neupogen; Neutrophils; Pegylation; Protein therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COUNT; BIOLOGICAL ACTIVITY; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; SPLEEN CELL; VESICULAR STOMATITIS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOCONJUGATES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS;

EID: 84884799254     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-75     Document Type: Article

References (57)

1. Granulocyte colony-stimulating factor and its receptor. Demetri GD, Griffin JD, Blood 1991 78 2791 2808 1720034
2. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Lyman GH, Expert Opin Biol Ther 2005 5 1635 1646 10.1517/14712598.5.12.1635 16318427 (Pubitemid 41771854)
3. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Metcalf D, Science 1991 254 529 533 10.1126/science.1948028 1948028 (Pubitemid 21917365)
4. Lineage-specific hematopoietic growth factors. Kaushansky K, N Engl J Med 2006 354 2034 2045 10.1056/NEJMra052706 16687716
5. Colony-stimulating factors for febrile neutropenia during cancer therapy. Bennett CL, Djulbegovic B, Norris LB, Armitage JO, N Engl J Med 2013 368 1131 1139 10.1056/NEJMct1210890 23514290
6. Clinical applications of granulocyte-colony stimulating factor. Sung L, Dror Y, Front Biosci 2007 12 1988 2002 10.2741/2204 17127437
7. Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Pojda Z, Molineux G, Dexter TM, Exp Hematol 1990 18 27 31 1688807 (Pubitemid 20028395)
8. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Molineux G, Pojda Z, Dexter TM, Blood 1990 75 563 569 1688718 (Pubitemid 20069192)
9. The kinetics of murine hematopoietic stem cells in vivo in response to prolonged increased mature blood cell production induced by granulocyte colony-stimulating factor. de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W, Blood 1995 86 2986 2992 7579391
10. Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice. Tanikawa S, Nakao I, Tsuneoka K, Nara N, Exp Hematol 1989 17 883 888 2475360 (Pubitemid 19217183)
11. Stimulatory effects of granulocyte colony-stimulating factor on colony-forming units-spleen (CFU-S) differentiation and pre-CFU-S proliferation in mice. Tanaka T, Suda T, Suda J, Inoue T, Hirabayashi Y, Hirai H, Takaku F, Miura Y, Blood 1991 77 2597 2602 1710513
12. Acceleration of the hemopoietic reconstitution in mice undergoing bone marrow transplantation by recombinant human granulocyte colony-stimulating factor. Tamura M, Yoshino T, Hattori K, Kawamura A, Nomura H, Imai N, Ono M, Transplantation 1991 51 1166 1170 10.1097/00007890-199106000-00005 1710841
13. The phagocytes: neutrophils and monocytes. Dale DC, Boxer L, Liles WC, Blood 2008 112 935 945 10.1182/blood-2007-12-077917 18684880
14. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Muller-Ruchholtz W, Schmitz N, Br J Haematol 1994 87 609 613 10.1111/j.1365-2141.1994.tb08321.x 7527648 (Pubitemid 24230031)
15. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM, Lancet 1992 339 640 644 10.1016/0140-6736(92)90795-5 1371817
16. Amgen I, Neulasta (Pegfilgrastim) (2008) and Neupogen (Filgrastim) (2007) prescribing information CA, USA: Amgen, Thousand Oaks 2008
17. PEG drugs: an overview. Greenwald RB, J Control Release 2001 74 159 171 10.1016/S0168-3659(01)00331-5 11489492 (Pubitemid 32727618)
18. The impact of PEGylation on biological therapies. Veronese FM, Mero A, BioDrugs 2008 22 315 329 10.2165/00063030-200822050-00004 18778113
19. Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Morishita M, Leonard RC, Expert Opin Biol Ther 2008 8 993 1001 10.1517/14712598.8.7.993 18549328 (Pubitemid 352007009)
20. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G, J Clin Oncol 2000 18 2522 2528 10893282 (Pubitemid 30432517)
21. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. Yang BB, Lum PK, Hayashi MM, Roskos LK, J Pharm Sci 2004 93 1367 1373 10.1002/jps.20024 15067712 (Pubitemid 38529709)
22. Polymer therapeutics: concepts and applications. Haag R, Kratz F, Angew Chem Int Ed Engl 2006 45 1198 1215 10.1002/anie.200502113 16444775 (Pubitemid 44097641)
23. PEGylation, successful approach to drug delivery. Veronese FM, Pasut G, Drug Discov Today 2005 10 1451 1458 10.1016/S1359-6446(05)03575-0 16243265 (Pubitemid 41483874)
24. Site-specific pegylation of G-CSF by reversible denaturation. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasut G, Bioconjug Chem 2007 18 1824 1830 10.1021/bc070123+ 17941684 (Pubitemid 350219980)
25. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Gaberc-Porekar V, Zore I, Podobnik B, Menart V, Curr Opin Drug Discov Devel 2008 11 242 250 18283612 (Pubitemid 351281064)
26. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS, Arthritis Res Ther 2006 8 12 10.1186/ar1861 16356199
27. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G, Cancer 2007 110 103 111 10.1002/cncr.22739 17516438 (Pubitemid 46986423)
28. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Richter AW, Akerblom E, Int Arch Allergy Appl Immunol 1984 74 36 39 10.1159/000233512 6706424 (Pubitemid 14136479)
29. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P, Expert Opin Drug Deliv 2012 9 1319 1323 10.1517/17425247.2012.720969 22931049
30. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Mihara M, Koishihara Y, Fukui H, Yasukawa K, Ohsugi Y, Immunology 1991 74 55 59 1718855
31. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR, J Immunol 1993 151 1235 1244 8393043 (Pubitemid 23219259)
32. Cytokine/Antibody complexes: an emerging class of immunostimulants. Mostbock S, Curr Pharm Des 2009 15 809 825 10.2174/138161209787582174 19275644
33. Optimizing the binding affinity of a carrier protein: a case study on the interaction between soluble ifnar2 and interferon beta. Peleg-Shulman T, Roisman LC, Zupkovitz G, Schreiber G, J Biol Chem 2004 279 18046 18053 10.1074/jbc.M400033200 14960565 (Pubitemid 38560574)
34. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J, Science 2006 311 1924 1927 10.1126/science.1122927 16484453
35. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. Stoklasek TA, Schluns KS, Lefrancois L, J Immunol 2006 177 6072 6080 17056533 (Pubitemid 44628822)
36. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J, Proc Natl Acad Sci USA 2006 103 9166 9171 10.1073/pnas.0600240103 16757567 (Pubitemid 43902550)
37. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR, J Immunol 2008 180 2099 2106 18250415
38. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M, J Immunol 2006 177 306 314 16785526 (Pubitemid 43939142)
39. IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Rubinstein MP, Lind NA, Purton JF, Filippou P, Best JA, McGhee PA, Surh CD, Goldrath AW, Blood 2008 112 3704 3712 10.1182/blood-2008-06-160945 18689546
40. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR, Blood 1994 84 1737 1746 7521686 (Pubitemid 24286121)
41. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC, Immunity 1996 5 491 501 10.1016/S1074-7613(00)80504-X 8934575 (Pubitemid 26423476)
42. Flow cytometric identification of murine neutrophils and monocytes. Lagasse E, Weissman IL, J Immunol Methods 1996 197 139 150 10.1016/0022-1759(96) 00138-X 8890901 (Pubitemid 26342018)
43. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI, J Immunol 2008 181 5791 5802 18832739
44. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA, Blood 2008 111 4233 4244 10.1182/blood-2007-07-099226 18272812
45. Long-term overexpression of human granulocyte colony-stimulating factor in transgenic mice: persistent neutrophilia with no increased mortality for more than one year. Serizawa I, Amano K, Ishii H, Ichikawa T, Kusaka M, Taguchi T, Kiyokawa N, Fujimoto J, Cytokine 2000 12 630 635 10.1006/cyto.2000.0669 10843738 (Pubitemid 30453491)
46. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC, Immunity 2002 17 413 423 10.1016/S1074-7613(02)00424-7 12387736 (Pubitemid 35223531)
47. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME, Nat Rev Cancer 2008 8 299 308 10.1038/nrc2355 18354418 (Pubitemid 351430867)
48. Myeloid-derived suppressor cells as regulators of the immune system. Gabrilovich DI, Nagaraj S, Nat Rev Immunol 2009 9 162 174 10.1038/nri2506 19197294
49. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V, Immunol Rev 2008 222 162 179 10.1111/j.1600-065X.2008.00602.x 18364001 (Pubitemid 351430364)
50. The role of G-CSF in adaptive immunity. Franzke A, Cytokine Growth Factor Rev 2006 17 235 244 10.1016/j.cytogfr.2006.05.002 16807060 (Pubitemid 44038619)
51. G-CSF-treated granulocytes inhibit acute graft-versus-host disease. Vasconcelos ZF, Dos Santos BM, Farache J, Palmeira TS, Areal RB, Cunha JM, Barcinski MA, Bonomo A, Blood 2006 107 2192 2199 10.1182/blood-2005-08-3239 16249380 (Pubitemid 43289406)
52. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, Layton JE, Green MD, Souza L, Fox RM, Lancet 1989 2 891 895 2477656
53. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). Salem ML, Diaz-Montero CM, Al-Khami AA, El-Naggar SA, Naga O, Montero AJ, Khafagy A, Cole DJ, J Immunol 2009 182 2030 2040 10.4049/jimmunol.0801829 19201856
54. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Hamilton SE, Wolkers MC, Schoenberger SP, Jameson SC, Nat Immunol 2006 7 475 481 16604076
55. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Kim SK, Reed DS, Olson S, Schnell MJ, Rose JK, Morton PA, Lefrancois L, Proc Natl Acad Sci USA 1998 95 10814 10819 10.1073/pnas.95.18.10814 9724787 (Pubitemid 28413151)
56. Development and function of agonist-induced CD25 + Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. D'Cruz LM, Klein L, Nat Immunol 2005 6 1152 1159 10.1038/ni1264 16227983 (Pubitemid 41541793)
57. Turnover of naive- and memory-phenotype T cells. Tough DF, Sprent J, J Exp Med 1994 179 1127 1135 10.1084/jem.179.4.1127 8145034 (Pubitemid 24091771)